PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives

Radiation Oncology

Table 1 First reports on biochemical response following PSMA based radiotherapy after prior radical treatment of the prostate

Referal for salvage/ non primary radiotherapy, PSA response
Author	Number of irradiated patients	Treatment of	Median PSA value	ADT use before radiotherapy	Follow up time (months)	PSA response during follow up	Re-Radiation	ADT initiation during follow up
Henkenberens [69]	23	N, Ma,	2.75	0%	12.4	52%	26%	22%
Zschaeck [59]	20 (11)	T, N, Ma, Mb	0.95	45% (0%)	29.0	70% (73%)	15% (27%)	5% (9%)
Bluemel [70]	43	T, N, Ma, Mb	0.60	0%	8.1	83%^a	0%	n.a.
Emmett [58]	99	T, N, Ma, Mb	0.28	0%	10.5	72%	n.a.	n.a.
Habl [61]	15	Mb	1.99	20%	22.5	20%	7%	n.a.
Henkenberens [71]	29	T, N, Ma, Mb	1.47	38%	8.3	96%	7%	0%
Guler [68]	23	N, Ma, Mb	1.10	100% (43%^b)	7.0	83%	0%	9%

T = local recurrence, N = pelvic lymph nodes, Ma = extrapelvic lymph nodes, Mb = bony metastases. ADT androgen deprivation therapy
^aFollow up only available for 21 patients: 20 presenting good response, however 3 patients with rising PSA values during salvage irradiation were included to the non-responders (4/24 patients)
^b43% of patients presented with hormone refractory situation after long-term ADT

ISSN: 1748-717X